This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Zydelig
  • /
  • A Phase II Study of Anti-PD-1 Antibody (MK-3475) i...
Clinical trial

A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL)

Read time: 2 mins
Last updated:2nd Feb 2015
Identifier: NCT02332980
This phase II trial studies how well pembrolizumab alone or with idelalisib or ibrutinib works in treating patients with chronic lymphocytic leukemia or other low-grade B-cell non-Hodgkin lymphomas that have returned after a period of improvement or have not responded to treatment. Monoclonal antibodies, such as pembrolizumab, block cancer growth in different ways by targeting certain cells and allow the immune system to attack the cancer. Idelalisib and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab alone or with idelalisib or ibrutinib may be an effective treatment in patients with chronic lymphocytic leukemia or other low-grade B-cell non-Hodgkin lymphomas.
Category Value
Date last updated at source 2017-05-08
Study type(s) Interventional
Expected enrolment 68
Study start date 2015-02-02
Estimated primary completion date 2020-01-01

View full details